Bifogade filer
PDF
Kurs
+14,29%
Likviditet
0,30 MSEK
Kalender
| Est. tid* | ||
| 2025-06-26 | 08:50 | Bokslutskommuniké 2025 |
| 2025-03-13 | - | Kvartalsrapport 2025-Q3 |
| 2025-01-08 | - | Extra Bolagsstämma 2025 |
| 2024-11-28 | - | Kvartalsrapport 2025-Q2 |
| 2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2024-09-16 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-26 | - | Bokslutskommuniké 2024 |
| 2024-03-27 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-21 | - | Kvartalsrapport 2024-Q2 |
| 2023-11-15 | - | Extra Bolagsstämma 2024 |
| 2023-10-27 | - | Årsstämma |
| 2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2023-09-20 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-23 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | Extra Bolagsstämma 2023 |
| 2023-03-28 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-21 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-31 | - | Årsstämma |
| 2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2022-09-29 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-29 | - | Bokslutskommuniké 2022 |
| 2022-03-21 | - | Kvartalsrapport 2022-Q3 |
| 2022-03-15 | - | Extra Bolagsstämma 2022 |
| 2021-12-29 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2021-09-29 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-24 | - | Bokslutskommuniké 2021 |
| 2021-03-16 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-14 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-20 | - | Årsstämma |
| 2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2020-09-28 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-25 | - | Bokslutskommuniké 2020 |
| 2020-03-12 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-17 | - | Kvartalsrapport 2020-Q2 |
| 2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2019-10-15 | - | Årsstämma |
| 2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2018-09-26 | - | Årsstämma |
| 2018-06-18 | - | Extra Bolagsstämma 2019 |
| 2018-06-12 | - | Bokslutskommuniké 2018 |
| 2018-03-12 | - | Kvartalsrapport 2018-Q3 |
| 2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2017-09-25 | - | Årsstämma |
| 2017-09-11 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-19 | - | Bokslutskommuniké 2017 |
| 2017-03-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-01-01 | - | Extra Bolagsstämma 2018 |
| 2016-11-30 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2016-09-05 | - | Årsstämma |
| 2016-09-05 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-13 | - | Bokslutskommuniké 2016 |
| 2016-02-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-16 | - | Extra Bolagsstämma 2017 |
| 2015-11-30 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2015-09-07 | - | Årsstämma |
| 2015-09-07 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-16 | - | Bokslutskommuniké 2015 |
| 2015-03-16 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-01 | - | Kvartalsrapport 2015-Q2 |
| 2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2014-10-06 | - | Årsstämma |
| 2014-10-06 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI's live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
The HoloMonitor CellSync marks the first in a series of models, with the long-term goal of delivering a clinical-grade product designed to set a new standard for automated quality control in cell and gene therapy manufacturing. The series is expected to include the latest developments in image processing and artificial intelligence.
Manufactured by our production partner in accordance with ISO 9001 standards, the HoloMonitor CellSync builds on the success of its predecessor, offering non-invasive, real-time imaging of live cells. It incorporates the latest advancements in PHI's core imaging technology, including an updated camera module and enhanced automated cell segmentation, which has been developed over the past two years.
"We're excited to take this next step in advancing our technology," says Ivan Jurković, CEO of Phase Holographic Imaging. "Having met our targets for the first half of 2025, we are well on track to finalize the first clinically applicable version of HoloMonitor."
HoloMonitor CellSync is expected to launch in the second half of 2025.
For additional information, please contact:
Ivan Jurkovic
E-mail: ir@phiab.com
Web: www.phiab.com - Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology - an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.